Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;22(2):217-240.
doi: 10.1007/s11154-021-09635-3. Epub 2021 Mar 23.

Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives

Federico Boscari  1 , Angelo Avogaro  2
Affiliations
Review

Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives

Federico Boscari et al. Rev Endocr Metab Disord. 2021 Jun.

Abstract

Type 1 diabetes mellitus imposes a significant burden of complications and mortality, despite important advances in treatment: subjects affected by this disease have also a worse quality of life-related to disease management. To overcome these challenges, different new approaches have been proposed, such as new insulin formulations or innovative devices. The introduction of insulin pumps allows a more physiological insulin administration with a reduction of HbA1c level and hypoglycemic risk. New continuous glucose monitoring systems with better accuracy have allowed, not only better glucose control, but also the improvement of the quality of life. Integration of these devices with control algorithms brought to the creation of the first artificial pancreas, able to independently gain metabolic control without the risk of hypo- and hyperglycemic crisis. This approach has revolutionized the management of diabetes both in terms of quality of life and glucose control. However, complete independence from exogenous insulin will be obtained only by biological approaches that foresee the replacement of functional beta cells obtained from stem cells: this will be a major challenge but the biggest hope for the subjects with type 1 diabetes. In this review, we will outline the current scenario of innovative diabetes management both from a technological and biological point of view, and we will also forecast some cutting-edge approaches to reduce the challenges that hamper the definitive cure of diabetes.

Keywords: Artificial pancreas; Islet transplantation; Pancreas transplantation; Stem cells; Technology; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Artificial pancreas components, its limitations, and future perspectives: The algorithm modifies automatic insulin infusion throughout the insulin pump based on glucose values registered by CGM to optimize glucose control increasing time spent in a target (70–180 mg/dl). Challenges are related to insulin absorption that should be accelerated, CGM accuracy, and the need for calibration. To reduce the burden related to diabetes a full closed-loop control that minimizes the subject's intervention could completely automatize insulin therapy. FLCL: full closed-loop control, CGM: continuous glucose monitoring
Fig. 2
Fig. 2
Different steps in diabetes onset and management, actual and future perspectives.. In each phase of diabetes onset different approaches are described in second column and actual and future perspectives are described in third column
See this image and copyright information in PMC

References

    1. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977–86. 10.1056/NEJM199309303291401. PMID: 8366922. - PubMed
    1. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000 Feb 10;342(6):381–9. 10.1056/NEJM200002103420603. Erratum in: N Engl J Med 2000 May 4;342(18):1376. PMID: 10666428; PMCID: PMC2630213. - PMC - PubMed
    1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643–53. 10.1056/NEJMoa052187. PMID: 16371630; PMCID: PMC2637991. - PMC - PubMed
    1. Umpierrez G, Korytkowski M. Diabetic emergencies—ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12:222–232. doi: 10.1038/nrendo.2016.15. - DOI - PubMed
    1. Leese GP, Wang J, Broomhall J. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176–1180. doi: 10.2337/diacare.26.4.1176. - DOI - PubMed

Publication types

LinkOut - more resources